Analysts Wells Fargo, Leerink Partners, and Guggenheim Initiate Coverage of Scribe Therapeutics (SCTX) with Target Prices Indicating Significant Upside Potential
Analysts are optimistic about Scribe Therapeutics' growth potential following its recent IPO, with price targets suggesting significant upside for investors. The company's innovative gene-editing technologies position it favorably in the competitive biotech landscape.